# EDGAR Filing Document

**Accession Number:** 0001374339
**File Stem:** 0000899243-23-008737
**Filing Date:** 2023-3
**Character Count:** 9557
**Document Hash:** 28d682ba1359de66365b5ca0626f3591
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-008737.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0000899243-23-008737

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230308

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kaplan Johanne
- **CENTRAL INDEX KEY:** 0001967717

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41429
- **FILM NUMBER:** 23739199

**MAIL ADDRESS:**
- **STREET 1:** PROMIS NEUROSCIENCES INC.
- **STREET 2:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ProMIS Neurosciences Inc.
- **CENTRAL INDEX KEY:** 0001374339
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2
- **BUSINESS PHONE:** 416-847-6898

**MAIL ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMORFIX LIFE SCIENCES LTD
- **DATE OF NAME CHANGE:** 20060831

## Ex-24

```
<PRE>
                           LIMITED POWER OF ATTORNEY

       The undersigned hereby constitutes and appoints Gail Farfel, Ph.D., and
Max Milbury the undersigned's true and lawful attorney-in-fact to:

      (1)    execute for and on behalf of the undersigned, in the undersigned's
capacity as officer and/or director of ProMIS Neurosciences Inc. (the "Company")
,from time to time the following U.S. Securities and Exchange Commission ("SEC")
forms: (i) Form ID, including any attached documents (such as Update Passphrase
Authentication), to effect the assignment of codes to the undersigned to be used
in the transmission of information to the SEC using the EDGAR System; (ii) Form
3, Initial Statement of Beneficial Ownership of Securities, including any
attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership
of Securities, including any attached documents; (iv) Form 5, Annual Statement
of Beneficial Ownership of Securities in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended, and the rules thereunder, including
any attached documents; (v) Schedules 13D and 13G; and (vi) amendments of each
thereof, in accordance with the Securities Exchange Act of 1934, as amended, and
the rules thereunder, including any attached documents;

     (2)    do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4
or 5, Schedule 13D or 13G, or any amendment(s) thereto and timely file such
form(s) with the SEC and any securities exchange, national association or
similar authority; and

    (3)    take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact, acting singly,
full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended.  The undersigned hereby agrees
to indemnify the attorneys-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorneys-in-fact.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee
of the Company.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of March 1, 2023.

                               /s/Johanne Kaplan
                               --------------------------
                               Signature

                               Johanne Kaplan
                               --------------------------
                               Print Name

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kaplan Johanne<br><sub>(Last) (First) (Middle)</sub><br>C/O PROMIS NEUROSCIENCES INC.,<br>1920 YONGE STREET, SUITE 200<br><sub>(Street)</sub><br>TORONTO, A6 M4S 3E2<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>ProMIS Neurosciences Inc. [ PMN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-08 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Development Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Shares | 6317 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Option (right to buy) | <sup>(2)</sup> | 2026-07-20 | Common Shares | 16666 | 9.00<sup>(1)</sup> | D |  |
| Option (right to buy) | <sup>(2)</sup> | 2026-12-14 | Common Shares | 8333 | 10.20<sup>(1)</sup> | D |  |
| Option (right to buy) | <sup>(2)</sup> | 2029-01-02 | Common Shares | 16666 | 15.00<sup>(1)</sup> | D |  |
| Option (right to buy) | <sup>(3)</sup> | 2031-12-09 | Common Shares | 33333 | 8.40<sup>(1)</sup> | D |  |
| Warrants (right to buy) | 2019-01-23 | 2024-01-22 | Common Shares | 4817 | 28.80<sup>(1)</sup> | D |  |

---

### Footnotes:

(1) Conversion or exercise price is in Canadian dollars.

(2) This option is fully vested and exercisable as of the date hereof.

(3) The option agreement provides that the option vests ratably over 48 months following the date of grant (December 9, 2021).

**Remarks:**
Exhibit List: Exhibit 24 - Power of Attorney

**Signature:** /s/ Max Milbury, Attorney-in-Fact for Johanne Kaplan  
**Date:** 2023-03-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**